2 Corporate Drive, First Floor
South San Francisco
About Senti Biosciences
Senti Biosciences is a next-generation therapeutics company that is developing gene circuits and programming cells for tremendous therapeutic value. Senti’s mission is to outsmart complex diseases with more intelligent medicines that will transform people’s lives. By programming cells to respond, adapt and make decisions, Senti is creating smarter therapies with computer-like logic, enhanced functionality and greater therapeutic control.
Senti’s product candidates address major challenges in cancer treatment. To overcome cancer immune evasion, Senti is building cell therapies equipped with combinatorial arming gene circuits to elicit broad and sustained anti-tumor immune responses. Senti is also developing next-generation cell therapies that more precisely target and eliminate cancer cells while sparing healthy tissue.
Senti Biosciences is based in South San Francisco and was founded in 2016 by Drs. Tim Lu, Philip Lee, Jim Collins and Wilson Wong. Senti is proud to count NEA, 8VC, Amgen Ventures, Lux Capital, Menlo Ventures, Pear Ventures, Allen & Company, Nest.Bio, Omega Funds, and LifeForce Capital among its investors.
Sentio Biosciences, Inc.
16 articles with Senti Biosciences
Senti Bio, a leading gene circuit company, announced that Dr. Tim Lu, the CEO of Senti Bio, will present a corporate overview at the virtual 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12th at 2:35 p.m. ET.
Backed by Leaps by Bayer, Bay Area-based Senti Biosciences secured $105 million in a Series B financing round that will help the company advance its therapeutic pipeline of allogeneic chimeric antigen receptor natural killer (CAR-NK) cell therapies.
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
Presentations will showcase data on the potential of gene circuits to precisely target cancer and new preclinical data on SENTI-101
RoosterBio Partners with Senti Biosciences to Rapidly Translate Gene Circuit Cell Therapy into the ClinicCollaboration leverages cGMP clinical hMSC systems to accelerate gene modified cell therapy for solid tumors.
RoosterBio Inc. announces a clinical supply and manufacturing collaboration agreement with pioneering gene circuit company Senti Biosciences, Inc. (Senti) to accelerate the clinical translation of Senti’s gene-modified cell therapies for ovarian cancer and other solid tumor indications. The collaboration will leverage RoosterBio’s human mesenchymal stem/stromal cell (hMSC) bioprocess systems, rapid product and process development platform, and
3/6/2020Life sciences and pharma companies from across the globe strengthen their leadership teams and board with this week's Movers & Shakers.
Pioneering gene circuit company recruits experienced biopharmaceutical executive to drive clinical development of its novel cell and gene therapy programs
Senti Biosciences, Inc., the gene circuit company focused on outsmarting complex diseases with intelligent medicines, will participate in the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.
10/18/2019Pharma, biotech and medtech companies strengthen their executive ranks and boards with this week's Movers & Shakers.
Leading gene circuit company recruits experienced drug developer for board of directors’ position to help steward clinical translation of gene circuit therapies
Leading gene circuit company taps veteran biotech executive for board of director position to help steward company growth, develop its integrated drug development capabilities, and guide business strategy
Synthetic biology company taps veteran biotech executive to drive next-generation cell and gene therapy programs into the clinic
South San Francisco-based Senti Biosciences is getting a new Chief Financial Officer and Chief Business Officer. Former Sangamo Therapeutics Senior Vice President and Chief Business Officer Curt Herberts will join Senti later this month.
Herberts joins Senti after successful tenure at Sangamo Therapeutics, where he led corporate development for the genome editing company
Senti Biosciences, based in South San Francisco, has completed a $53 million Series A financing.
Founded by pioneers in the field of synthetic biology, Senti Biosciences' platform enables the design of adaptive therapies for challenging diseases. Series A round led by prominent investment firm New Enterprise Associates (NEA) along with other top investors.